2026-06-14T05:17:53Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/200882024-11-29T04:13:09Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967

00925njm 22002777a 4500 dc Pagonabarraga, Javier author Pinol, Gerard author Cardozo, Adriana author Sanz, Pilar author Puente, Victor author Otermin, Pilar author Legarda, Inés author Delgado, Tania author Serrano, Carmen author Balaguer, Ernest author Aguirregomozcorta, Maria author Alvarez, Ramiro author Kulisevsky, Jaime J. author 2015 Sleep disturbances occur frequently in patients with Parkinson's disease (PD). The aim of this study was to investigate the effects of rotigotine on sleep fluctuations in a sample of PD patients with self-reported complaints of nocturnal awakenings. This prospective, open-label, observational, and multicenter study enrolled consecutive outpatients with PD and administered rotigotine (mean dose 8.9 mg/day) for 3 months. The primary endpoint was the change from baseline in sleep fragmentation, assessed using the sleep maintenance subscale score of the Parkinson's Disease Sleep Scale (PDSS). The newly designed Parkinson's Disease Sleep Fragmentation Questionnaire (PD-SFQ) was used to measure other sleep parameters. A total of 62 patients were enrolled (mean age 70.2 years; 66% male). At 3 months, rotigotine significantly improved sleep fragmentation from baseline on the PDSS-2 sleep maintenance subscale (from 3.4 +/- 0.9 to 1.9 +/- 1.4; P < 0.0001). Rotigotine also significantly improved nocturnal motor symptoms (P < 0.0001), restless legs-like symptoms (P < 0.005), and nocturia (P = 0.004). Rotigotine significantly improved self-reported complaints of sleep fragmentation in PD patients and could be a useful treatment to improve this specific sleep problem in PD. However, these results are based on a small and clinically heterogeneous sample so they must be taken cautiously. Pagonabarraga J, Pinol G, Cardozo A, Sanz P, Puente V, Otermin P, et al. Transdermal Rotigotine Improves Sleep Fragmentation in Parkinson's Disease: Results of the Multicenter, Prospective SLEEP-FRAM Study. Parkinsons Dis. 2015;2015:131508. Epub 2015 Feb 22. 10.1155/2015/131508 2042-0080 2090-8083 Parkinsons Disease http://hdl.handle.net/20.500.13003/11033 25793143 L602813013 2-s2.0-84924529872 http://hdl.handle.net/20.500.12105/20088 351081200001 Transdermal Rotigotine Improves Sleep Fragmentation in Parkinson's Disease: Results of the Multicenter, Prospective SLEEP-FRAM Study